D-1293-2022 Class II Terminated
FDA drug recall D-1293-2022 was initiated by Jubilant Cadista Pharmaceuticals, Inc. on Jul 18, 2022 and is designated Class II. Reason for recall: Failed dissolution specifications. The recall status is terminated (terminated Nov 22, 2022). Affected quantity: 9,600 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Aug 3, 2022
- Initiation Date
- Jul 18, 2022
- Termination Date
- Nov 22, 2022
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 9,600 bottles
Product description
Irbesartan Tablets, USP, 150mg, 90- count bottles, Rx only, Manufactured by: Jubilant Generics Ltd. Roorkee- 247661, India, Marketed by: Jubilant Cadista Pharmaceuticals Inc. Salisbury, MD 21801, USA, NDC 59746-448-90
Reason for recall
Failed dissolution specifications.
Distribution pattern
Nationwide within the United States
Code information
Lot #: IB220023A, exp. date 08/2022
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-1293-2022
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026